IRTC earnings analysis
What we found in IRTC's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
iRhythm Holdings reported robust Q1 2026 results, with revenue reaching $199.4 million, exceeding estimates by 2.8%. Additionally, the company significantly improved its diluted EPS to a loss of $0.35 from an expected loss of $0.62, marking an impressive 55% reduction in net loss year-on-year, driven by increased volume in iRhythm Services despite ongoing cost pressures.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Strong Revenue Growth
- Revenue for Q1 2026 was $199.4 million, a 26% increase from $158.7 million in Q1 2025.
- Improved EPS Performance
- Diluted EPS loss was $0.35, better than the expected loss of $0.62, and a significant reduction from a loss of $0.97 in Q1 2025.
- Successful Cost Management
- Cost of revenue increased at a lower rate (17%) than revenue growth (26%), leading to an improvement in gross profit.
- Increased Revenue Guidance
- Management raised full-year revenue guidance to $875 million - $885 million, reflecting confidence in ongoing demand.
- Positive Cash Flow from Investing
- Cash provided by investing activities was $30.2 million, a notable improvement from cash used of $38.1 million in Q1 2025.
- Ongoing Market Expansion
- The company reported increased utilization of its home enrollment service in response to the demand for remote cardiac monitoring.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Litigation Costs
- Increased legal expenses related to ongoing litigation, including $3.7 million incurred in Q1 2026 for intellectual property disputes.
- Rising Operational Costs
- The cost of revenue increased by $8.6 million, or 17%, impacting margins despite revenue growth.
- Regulatory Compliance Risks
- Ongoing scrutiny from FDA regarding compliance with medical device regulations, following the warning letter issued in May 2023.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $-0.35
- Gross margin
- 70.7%
- Operating margin
- -8.1%
- Segment
- iRhythm Services
- Segment
- Home Enrollment Services
What they said about what is next.
Management anticipates continued growth due to increasing demand for remote cardiac monitoring services.
The filing reads better than the one before it.
What came before.
- 10-K · February 19, 2026
- iRhythm positions itself as the market leader in long-term continuous ambulatory cardiac monitoring (LTCM) with a dominant Zio platform and a large addressable market; the 2025 results show volume-driven revenue growth,…
- 10-Q · August 1, 2024
- iRhythm reported Q2 revenue of $148,047,000 (up from $131,929,000 in Q1 2024 and $124,130,000 in Q2 2023) and GAAP net loss per share of $(0.65). Gross margin was 69.9% while loss from operations was $(22,981,000); cash…
- 10-Q · May 2, 2024
- Revenue grew to $131.929M in Q1 2024 (+$20.493M, +18.4% vs Q1 2023) with gross margin roughly stable at ~66.3%. Operating loss improved slightly to $(38.138)M, but net loss widened to $(45.667)M due largely to financing…
- 10-K · February 23, 2023
- iRhythm positions itself as a scale-focused digital healthcare company that commercializes the Zio ambulatory cardiac monitoring platform; the company reports it has provided Zio Services to over five million patients…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing IRTC makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever